|
|
|
|
| LEADER |
02637nam a2200325 u 4500 |
| 001 |
EB002002378 |
| 003 |
EBX01000000000000001165279 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Yank, Veronica
|
| 245 |
0 |
0 |
|a Comparative effectiveness of in-hospital use of recombinant factor VIIa for off-label indications vs. usual care
|h Elektronische Ressource
|c prepared for, Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by, Stanford-UCSF Evidence-based Practice Center ; investigators, Veronica Yank ... [et al.]
|
| 260 |
|
|
|a Rockville, MD
|b Agency for Healthcare Research and Quality
|c 2010, [2010]
|
| 300 |
|
|
|a 1 PDF file (various pagings)
|b ill
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Factor VIIa / therapeutic use
|
| 653 |
|
|
|a Evidence-Based Medicine
|
| 653 |
|
|
|a Inpatients
|
| 653 |
|
|
|a Off-Label Use
|
| 653 |
|
|
|a Recombinant Proteins / therapeutic use
|
| 710 |
2 |
|
|a United States
|b Agency for Health Care Policy and Research
|
| 710 |
2 |
|
|a Stanford-UCSF Evidence-based Practice Center
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Comparative effectiveness review
|
| 500 |
|
|
|a "Contract No. 290-02-0017.". - "May 2010."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK98697
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This report evaluates the level of evidence currently available to support the effectiveness and safety of using recombinant activated coagulation factor VII (rFVIIa) for clinical indications not approved by the U.S. Food and Drug Administration (FDA). rFVIIa is approved for a variety of uses in hemophilia patients who have developed antibody inhibitors that compromise the use of standard factor replacement. Use of this costly biologic product has expanded beyond these hemophilia-related indications to encompass a range of off-label uses, most of which are in-hospital uses. These uses differ substantially from the drug's FDA approved label. The purpose of this report is two-fold: (1) To document the full range of clinical indications for which rFVIIa is being used and the types of studies available to evaluate these uses and (2) To provide a comparative effectiveness review of rFVIIa vs. usual care for several in-hospital clinical indications: intracranial hemorrhage, massive bleeding secondary to trauma, and the selected surgical procedures of cardiac surgery, liver transplantation, and prostatectomy
|